Manatuck Hill Partners LLC acquired a new stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 100,000 shares of the company's stock, valued at approximately $486,000. Manatuck Hill Partners LLC owned 0.54% of OptimizeRx at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Barclays PLC lifted its position in shares of OptimizeRx by 358.5% in the 3rd quarter. Barclays PLC now owns 26,934 shares of the company's stock worth $208,000 after acquiring an additional 21,060 shares during the period. SG Americas Securities LLC bought a new stake in OptimizeRx during the fourth quarter worth about $51,000. Greenwood Capital Associates LLC increased its holdings in shares of OptimizeRx by 31.5% during the fourth quarter. Greenwood Capital Associates LLC now owns 88,596 shares of the company's stock worth $431,000 after buying an additional 21,240 shares in the last quarter. AMH Equity Ltd raised its stake in shares of OptimizeRx by 25.0% in the fourth quarter. AMH Equity Ltd now owns 125,000 shares of the company's stock valued at $608,000 after acquiring an additional 25,000 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in OptimizeRx during the 4th quarter worth approximately $25,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other OptimizeRx news, Director James Paul Lang purchased 321,408 shares of the stock in a transaction on Friday, March 14th. The shares were purchased at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the purchase, the director now owns 389,452 shares of the company's stock, valued at approximately $2,959,835.20. This represents a 472.35 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.10% of the stock is currently owned by company insiders.
OptimizeRx Stock Up 0.5 %
Shares of NASDAQ OPRX traded up $0.05 during mid-day trading on Wednesday, reaching $9.38. 19,625 shares of the company's stock were exchanged, compared to its average volume of 267,149. The business has a fifty day simple moving average of $7.86 and a 200 day simple moving average of $6.23. OptimizeRx Co. has a twelve month low of $3.78 and a twelve month high of $14.13. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $173.46 million, a price-to-earnings ratio of -7.05 and a beta of 1.28.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on OPRX shares. JMP Securities restated a "market outperform" rating and set a $8.00 target price on shares of OptimizeRx in a report on Thursday, February 6th. Royal Bank of Canada reissued a "sector perform" rating and issued a $6.00 target price (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Finally, B. Riley upgraded OptimizeRx to a "strong-buy" rating in a research report on Wednesday, March 12th. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.06.
View Our Latest Stock Analysis on OPRX
About OptimizeRx
(
Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Featured Articles
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
